Sandgaard reiterated confidence in the NiCO pulse oximeter, with FDA approval anticipated within six months of submission. He projected commercialization and revenue generation to begin in 2026. Q1 ...

Q1 2025 Earnings Conference Call April 29, 2025 4:15 PM ETCompany ParticipantsBrian Prenoveau - IRThomas Sandgaard - ...

Philadelphia, Pennsylvania-- (Newsfile Corp. - April 28, 2025) - Berger Montague PC advises investors that a securities class action lawsuit has been filed against Zynex, Inc. ("Zynex" or the "Company ...

April 24, 2025) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a shareholder and consumer rights litigation firm, alerts investors that a securities class action lawsuit has been filed in the ...

A significant factor weighing on Zynex is the temporary suspension of payments from Tricare, its largest customer, as the insurer conducts a review of past claims. The company has also declined to ...

Berger Montague PC advises investors that a securities class action lawsuit has been filed against Zynex, Inc. ("Zynex" or the "Company") on behalf of purchasers of Zynex securities between March 13, ...

Tricare; (4) as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (5) as a result of ...

including Tricare; (4) that, as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government ...